Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models

Autor: Badiaa Bouzya, Ronan Nicolas Rouxel, Lionel Sacconnay, Romuald Mascolo, Laurence Nols, Stéphanie Quique, Loïc François, Anne Atas, Lucile Warter, Nancy Dezutter, Clarisse Lorin
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: npj Vaccines, Vol 8, Iss 1, Pp 1-10 (2023)
Druh dokumentu: article
ISSN: 2059-0105
35366397
DOI: 10.1038/s41541-023-00729-4
Popis: Abstract Respiratory syncytial virus (RSV) causes a high disease burden in older adults. An effective vaccine for this RSV-primed population may need to boost/elicit robust RSV-neutralizing antibody responses and recall/induce RSV-specific T cell responses. To inform the selection of the vaccine formulation for older adults, RSVPreF3 (RSV fusion glycoprotein engineered to maintain the prefusion conformation) with/without AS01 adjuvant was evaluated in mice and bovine RSV infection-primed cattle. In mice, RSVPreF3/AS01 elicited robust RSV-A/B-specific neutralization titers and RSV F-specific polyfunctional CD4+ T cell responses exceeding those induced by non-adjuvanted RSVPreF3. In primed bovines, RSVPreF3/AS01 tended to induce higher pre-/post-vaccination fold-increases in RSV-A/B-specific neutralization titers relative to non-adjuvanted and Alum-adjuvanted RSVPreF3 formulations, and elicited higher RSV F-specific CD4+ T cell frequencies relative to the non-adjuvanted vaccine. Though AS01 adjuvanticity varied by animal species and priming status, RSVPreF3/AS01 elicited/boosted RSV-A/B-specific neutralization titers and RSV F-specific CD4+ T cell responses in both animal models, which supported its further clinical evaluation as prophylactic candidate vaccine for older adults.
Databáze: Directory of Open Access Journals
Externí odkaz: